Open Orphan #ORPH – FDA Breakthrough Designation for Big Pharma RSV candidate

Vaccine candidate assessed in successful human challenge trial conducted by hVIVO  Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement dated 14 February 2022 from Bavarian Nordic A/S (“Bavarian Nordic”) (OMX: BAVA), reporting […]